New pill and immunotherapy combo tested for Hard-to-Treat cancers

NCT ID NCT06082960

Ongoing Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase study tests a new oral drug called GS-9911, alone or with an intravenous immunotherapy (zimberelimab), in 45 adults with advanced solid tumors who have run out of standard options. The main goals are to check safety, find the best dose, and see how the body handles the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GS-9911 (oral tablet) and zimberelimab (intravenous infusion)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

NEXT Oncology

San Antonio, Texas, 78229, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Smilow Cancer Hospital Phase 1 Unit

New Haven, Connecticut, 06520, United States
South Texas Accelerated Research Therapeutics, LLC

San Antonio, Texas, 78229, United States
University Health Network, Princess Margaret Cancer Centre

Toronto, M5G, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.